CD70 and neoplasm: This improved activation was also converted to improved killing of CD70+ tumor cell lines compared to CD70-CAR NK cells (Viable Raji: 16.8 ± 5.5% vs 25.9 ± 4.5%, viable PANC-1: 31.1 ± 5.9% vs 59.6 ± 4.2%, viable LIM2099: 45.3 ± 11.5% vs 85.5 ± 3.9%, respectively; Fig. 3J).